Tag
NASDAQ: IBB
- CareDx links elevated AlloSure Kidney to worse transplant outcomes
- Roche reports vamikibart vision gains through week 52 in two trials
- Asahi Kasei wins FDA approval for HOVILPRI in refractory HSV
- Johnson & Johnson reports at least 72% PASI 90 after two years
- Genmab A/S reports 51% lower progression or death risk in Phase 3 lymphoma trial
- Orexo AB (publ) proposes SEK250M rights issue ahead of drug milestones
- Rezolute says FDA recommends pre‑BLA meeting after congenital HI trial miss
- Sernova and Seraxis close US$11.2M financing for diabetes trial
- Stoke Therapeutics details Dravet cognition analysis after FDA meeting
- Vaxcyte reports VAX‑31 met all OPUS‑1 primary immune endpoints
- Eli Lilly and Company wins first-line Jaypirca approval for CLL/SLL
- Novo Nordisk A/S says FDA extends denecimig review over facility remediation
- Ultragenyx says EMA validates Sanfilippo gene therapy application
- Evaxion schedules November immune update after 2025 melanoma readout
- Summit Therapeutics plans Phase III Datroway breast cancer trial
- Wave Life Sciences plans two‑year WVE‑006 trial after FDA feedback
- United Therapeutics Corporation wins Yutrepia PH‑ILD patent ruling
- Immunome gains FDA IND clearance for IM‑1340 solid tumour study
- Egetis Therapeutics AB wins FDA approval for Emcitate in MCT8 deficiency
- Summit Therapeutics agrees to US$2B AstraZeneca equity investment
- MediciNova misses both Phase 2 endpoints despite HDL gains
- REGENXBIO reports three-year retinopathy improvement in 6 of 10
- Merck says remigromig met BRUNELLO vision endpoint, flags eye risks
- Gossamer Bio submits seralutinib NDA after Phase 3 endpoint miss
- Scancell signs up to US$25M debt facility for melanoma Phase 3
- Lantheus Holdings wins FDA approval for Bravnetsa before Curium vote
- Immunovant drops cutaneous lupus program after IMVT‑1402 trial miss
- Ionis Pharmaceuticals' Phase 3 kidney trial meets proteinuria endpoint